Rahul Prasad

Abstract

Aim: To assess and compare the role of topical nepafenac (0.1%) v/s bromfenac (0.09%) in sustaining intra-operative mydriasis while doing cataract extraction. Study Design: Prospective, randomized study. Place and Duration of Study: Regional Institute of Ophthalmology, Rajendra Institute of Medical Sciences (RIMS), Ranchi (Jharkhand). The duration of study was from June 2019 to February 2020. Materials and Methods: Topical NSAIDs (nepafenac and bromfenac) and carboxymethylcellulose (control) were administered to the cataract patients before Phaco surgery. Pupillary diameters were assessed first at starting of surgery and then after completing the surgery; average values were calculated for the three groups. Study was done on 90 patients having age 40-80 years, planned for cataract surgery with PCIOL implantation. Results: in group A (i.e. control) reduction in pupillary diameter came out to be more statistically significant unlike in group B (nepafenac) and in group C (bromfenac) (p Conclusion: Both nepafenac (0.1%) and bromfenac (0.09%) administered a day before operation are helpful in sustaining pupil size intra-operatively but bromfenac comparatively seemed to be better than nepafenac in sustaining mydriasis during SICS/Phaco. Keywords: Bromfenac, Cataract, Mydriasis, Nepafenac.

Open full article page

Abstract

The objective of this review is to emphasize on basic and clinical aspects of Neovascular glaucoma (NVG) as it is a severely blinding and intractable disease. Therefore, to prevent or reduce the extent of visual loss caused by NVG, a detailed knowledge of its causes, pathogenesis, pathology, methods of early diagnosis and management is of utmost importance. The most common diseases responsible for development of NVG are ischaemic central retinal vein occlusion (CRVO), diabetic retinopathy and ocular ischaemic syndrome. In management strategy, the key point is to maintain a high index of suspicion of development of NVG in at risk patients and prevent its development with appropriate management of causative disease. If NVG develops, early diagnosis and its management by various medical and surgical means should be done at earliest. Management of NVG essentially consists of controlling high IOP by medical and or surgical interventions. Currently we still do not have a satisfactory option for treating NVG and preventing the profound loss of vision. This review basically discusses the various advantages and limitations of various medical and surgical techniques which are being commonly employed. Keywords: Anti VGEF, Diabetic retinopathy, Glaucoma, Hypertensive retinopathy, Neovascularization, Retinal vein occlusion.

Open full article page